CAMBRIDGE, Mass. , ROTTERDAM, Netherlands and SUZHOU, China , Nov. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, is pleased to announce the appointment of Dr.
Raymond Zheng as Chief Business Officer (CBO). Based in the United States , Dr. Zheng will lead global business development and alliance management functions, reporting directly to Dr.
Jingsong Wang , Founder, Chairman and CEO of Harbour BioMed. In his new role, Dr. Zheng will seek to maximize the value of Harbour BioMed's product portfolio through effective execution of the Company's partnership initiatives.
He will also play a key role in optimizing resources and coordinating business development operations globally to support the Company's long-term strategic goals of investing in and developing transformative medicinal products to address key unmet medical needs. Dr. Zheng was initially trained as a scientist and completed a research fellowship in the field of translational oncology at Harvard Medical School before joining the biopharmaceutical industry.
Prior to Harbour BioMed, Dr. Zheng served as founder and CSO of Urica Therapeutics, a clinical-stage company developing an oral therapy for refractory gout. During his tenure at Urica, early clinical development was completed, and the asset was subsequently acquired by a Newco ba.